

**MEDITSIINISEADMETE BIOLOOGILINE HINDAMINE.
OSA 7: JÄÄGID ETÜLEENOKSIIDIGA STERILISEERIMISEST**

**Biological evaluation of medical devices - Part 7:
Ethylene oxide sterilization residuals (ISO 10993-7:2008
+ ISO 10993-7:2008/Amd 1:2019)**

EESTI STANDARDI EESSÕNA

NATIONAL FOREWORD

See Eesti standard EVS-EN ISO 10993-7:2008 +A1:2022 sisaldab Euroopa standardi EN ISO 10993-7:2008 ja selle muudatuse A1:2022 ja paranduse AC:2009 ingliskeelset teksti.	This Estonian standard EVS-EN ISO 10993-7:2008 +A1:2022 consists of the English text of the European standard EN ISO 10993-7:2008 and its amendment A1:2022 and its corrigendum AC:2009.
Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas. Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 15.10.2008, muudatus A1 12.01.2022.	This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation and Accreditation. Date of Availability of the European standard is 15.10.2008, for A1 12.01.2022.
Muudatusega A1 lisatud või muudetud teksti algus ja lõpp on tekstis tähistatud sümbolitega A1 A1 . Parandusega AC lisatud või muudetud teksti algus ja lõpp on tekstis tähistatud sümbolitega AC AC . Standard on kättesaadav Eesti Standardimis- ja Akrediteerimiskeskusest.	The start and finish of text introduced or altered by amendment A1 is indicated in the text by tags A1 A1 . The start and finish of text introduced or altered by corrigendum AC is indicated in the text by tags AC AC . The standard is available from the Estonian Centre for Standardisation and Accreditation.

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile standardiosakond@evs.ee.

ICS 11.100.20

Standardite reprodutseerimise ja levitamise õigus kuulub Eesti Standardimis- ja Akrediteerimiskeskusele

Andmete paljundamine, taastekitamine, kopeerimine, salvestamine elektroonsesse süsteemi või edastamine ükskõik millises vormis või millisel teel ilma Eesti Standardimis- ja Akrediteerimiskeskuse kirjaliku loata on keelatud.

Kui Teil on küsimusi standardite autoriõiguse kaitse kohta, võtke palun ühendust Eesti Standardimis- ja Akrediteerimiskeskusega: Koduleht www.evs.ee; telefon 605 5050; e-post info@evs.ee

The right to reproduce and distribute standards belongs to the Estonian Centre for Standardisation and Accreditation

No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, without a written permission from the Estonian Centre for Standardisation and Accreditation.

If you have any questions about standards copyright protection, please contact the Estonian Centre for Standardisation and Accreditation:

Homepage www.evs.ee; phone +372 605 5050; e-mail info@evs.ee

English Version

**Biological evaluation of medical devices - Part 7: Ethylene
oxide sterilization residuals (ISO 10993-7:2008 +
ISO 10993-7:2008/Amd 1:2019)**

Évaluation biologique des dispositifs médicaux - Partie
7: Résidus de stérilisation à l'oxyde d'éthylène (ISO
10993-7:2008 + ISO 10993-7:2008/Amd 1:2019)

Biologische Beurteilung von Medizinprodukten - Teil 7:
Ethylenoxid- Sterilisationsrückstände (ISO 10993-
7:2008 + ISO 10993-7:2008/Amd 1:2019)

This European Standard was approved by CEN on 23 September 2008. Amendment A1 was approved by CEN on 5 November 2019.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard and its amendment the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN Management Centre or to any CEN member.

This European Standard and its Amendment A1 exist in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Foreword

This document (EN ISO 10993-7:2008) has been prepared by Technical Committee ISO/TC 194 "Biological evaluation of medical devices" in collaboration with Technical Committee CEN/TC 206 "Biological evaluation of medical devices" the secretariat of which is held by NEN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by April 2009, and conflicting national standards shall be withdrawn at the latest by October 2011.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 10993-7:1995.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EC Directives.

For relationship with EC Directives, see informative Annexes ZA and ZB, which are an integral part of this document.

NOTE: The Essential Requirements of the Medical Devices Directives require that risks be reduced or eliminated as far as possible and, specifically, that risks posed by residues be minimized and risks posed by substances leaking from a device be reduced to a minimum. It is inherent in these Essential Requirements that, within the maximum limits specified by this standard, exposure to a genotoxic carcinogen should be reduced to levels as low as reasonably practicable, taking account of the generally acknowledged state of the art, the technological level existing at the time of design and technical and economic considerations compatible with a high level of health and safety.

According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

Endorsement notice

The text of ISO 10993-7:2008 has been approved by CEN as a EN ISO 10993-7:2008 without any modification.

A1 Amendment A1 European foreword

This document (EN ISO 10993-7:2008/A1:2022) has been prepared by Technical Committee ISO/TC 194 "Biological and clinical evaluation of medical devices" in collaboration with Technical Committee CEN/TC 206 "Biological and clinical evaluation of medical devices" the secretariat of which is held by DIN.

This Amendment to the European Standard EN ISO 10993-7:2008 shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by July 2022, and conflicting national standards shall be withdrawn at the latest by July 2022.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 10993-7:2008/Amd 1:2019 has been approved by CEN as EN ISO 10993-7:2008/A1:2022 without any modification. **A1**

Contents

Page

Foreword	iv
[A1] Amendment A1 foreword [A1]	vi
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Requirements	2
4.1 General	2
4.2 Categorization of devices	2
4.3 Allowable limits	3
4.3.1 General	3
4.3.2 Permanent contact devices	3
4.3.3 Prolonged exposure devices	3
4.3.4 Limited exposure devices	4
4.3.5 Tolerable contact limits for surface contacting devices and implants	4
4.3.6 Special situations	4
4.4 Determination of EO and ECH residuals	5
4.4.1 General	5
4.4.2 Determination of residue	6
4.4.3 Product sampling and sample "blank"	6
4.4.4 Sample/fluid ratios	7
4.4.5 Extraction time and conditions	7
4.4.6 Product extraction	8
4.4.7 Data analysis and interpretation	10
5 Product release	11
5.1 General	11
5.2 Release of products without dissipation curve data	11
5.3 Procedure for product release using residue dissipation curves	11
Annex A (normative) Evaluation of gas chromatograms	14
Annex B (informative) Gas chromatographic determination for EO and ECH	17
Annex C (informative) Flowchart and guidance for the application of this part of ISO 10993 series of standards to the determination of EO and ECH residuals in medical devices	21
Annex D (informative) Factors influencing product residual	29
Annex E (informative) Extraction conditions for determination of residual EO	31
Annex F (informative) Rationale for the provisions of this part of ISO 10993	32
Annex G (informative) Establishment of allowable limits for EO	37
Annex H (informative) Establishment of allowable limits for ECH	56
Annex I (informative) Establishment of allowable limits for EG	66
Annex J (informative) Preparation of EO and ECH standards	71
Annex K (informative) Ethylene oxide residue measuring methods	75

Annex ZA (informative) Relationship between this International Standard and the Essential Requirements of EU Directive 93/42/EEC Medical devices	83
Annex ZB (informative) Relationship between this International Standard and the Essential Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices	84
Bibliography	85

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 10993-7 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*.

This second edition cancels and replaces the first edition (ISO 10993-7:1995) which has been technically revised.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- **AC** Part 1: Evaluation and testing within a risk management process **AC**
- Part 2: Animal welfare requirements
- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
- Part 4: Selection of tests for interactions with blood
- Part 5: Tests for in vitro cytotoxicity
- Part 6: Tests for local effects after implantation
- Part 7: Ethylene oxide sterilization residuals
- Part 9: Framework for identification and quantification of potential degradation products
- Part 10: Tests for irritation and skin sensitization
- Part 11: Tests for systemic toxicity
- Part 12: Sample preparation and reference materials
- Part 13: Identification and quantification of degradation products from polymeric medical devices
- Part 14: Identification and quantification of degradation products from ceramics
- Part 15: Identification and quantification of degradation products from metals and alloys

- *Part 16: Toxicokinetic study design for degradation products and leachables*
- *Part 17: Establishment of allowable limits for leachable substances*
- *Part 18: Chemical characterization of materials*
- *Part 19: Physico-chemical, morphological and topographical characterization of materials* [Technical Specification]
- *Part 20: Principles and methods for immunotoxicology testing of medical devices* [Technical Specification]

A₁ Amendment A1 foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*.

A list of all parts in the ISO 10993 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html. **A₁**

Introduction

Requirements for the development, validation and routine control of an ethylene oxide sterilization process for medical devices are given in International Standards developed by ISO/TC 198. Certain requirements relating to medical devices for biological testing, selection of tests, and the allocation of devices to categories are dealt with in a variety of International Standards developed by ISO/TC 194. The specific requirement for ethylene oxide and other sterilization process residuals was referred to ISO/TC 194. Other International Standards delineate particular requirements for biological testing for specific products.

As noted in the introduction to ISO 11135-1:2007, when determining the suitability of ethylene oxide (EO) for sterilization of medical devices, it is important to ensure that the levels of residual EO, ethylene chlorohydrin (ECH) and ethylene glycol (EG) pose a minimal risk to the patient in normal product use. Therefore, it is important that the use of alternative materials and sterilization processes be considered during product design and development. EO is known to exhibit a number of biological effects. In the development of this part of ISO 10993, consideration was given to these effects, which include irritation, organ damage, mutagenicity and carcinogenicity in humans and animals, and reproductive effects in animals. Similar consideration was given to the harmful effects of ECH and EG. In practice, for most devices, exposure to EO and ECH is considerably lower than the maximum values specified in this part of ISO 10993.

Moreover, when the choice for EO sterilization has been made, irrespective of the provisions of this part of ISO 10993, exposure to EO residues should be minimized. Requirements herein are in addition to the biological evaluation and testing requirements for each individually designed medical device as indicated in ISO 10993-1. The biological evaluation and testing requirements, combined with the EO-sterilization process residue limits, form the justification that an EO-sterilized device is acceptable for use. Maximum allowable residues for ethylene chlorohydrin (ECH), when ECH has been found to be present in medical devices sterilized with EO, are also specified. Local effects (e.g., irritation) have been considered and are incorporated in the tolerable contact limit (TCL) as given in 4.3.5.2 and Annex G for EO, and in 4.3.5.3 and Annex H for ECH.

This document is a preview generated by EVS

Biological evaluation of medical devices —

Part 7:

Ethylene oxide sterilization residuals

1 Scope

This part of ISO 10993 specifies allowable limits for residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) in individual EO-sterilized medical devices, procedures for the measurement of EO and ECH, and methods for determining compliance so that devices may be released. Additional background, including guidance and a flowchart showing how this document is applied, are also included in the informative annexes.

EO-sterilized devices that have no patient contact (e.g., *in vitro* diagnostic devices) are not covered by this part of ISO 10993.

NOTE This part of ISO 10993 does not specify limits for ethylene glycol (EG).

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1:2018, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-3, *Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity*

ISO 10993-10, *Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity*

ISO 10993-12, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

ISO 10993-17:2002, *Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 10993-1, ISO 10993-17 and the following apply.

3.1

simulated-use extraction

extraction to demonstrate compliance with the requirements of this part of ISO 10993, by evaluating residue levels available to the patient or user from devices during the routine use of a device with water extraction to simulate product use